MedTrace Logo

Triumeq in Amyotrophic Lateral Sclerosis

NCT05193994 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 419

Last updated 2025-07-11

No results posted yet for this study

Summary

To determine if Triumeq improves survival in Amyotrophic Lateral Sclerosis (ALS) compared with placebo

Conditions

Interventions

DRUG

Dolutegravir, Abacavir and Lamivudine

Dolutegravir 50mg, Abacavir 600mg and Lamivudine 300mg.

DRUG

Placebo

Matching placebo.

Sponsors & Collaborators

  • King's College London

    collaborator OTHER

  • Stichting TRICALS Foundation

    collaborator OTHER

  • Macquarie University, Australia

    lead OTHER

Principal Investigators

  • Julian Gold, MD, FFPHM · Macquarie University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-24
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • Australia
  • Ireland
  • Netherlands
  • New Zealand
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05193994 on ClinicalTrials.gov